Altium Capital Management LLC Raises Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Altium Capital Management LLC boosted its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 2.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,395,000 shares of the biotechnology company's stock after buying an additional 35,000 shares during the quarter. ADMA Biologics accounts for approximately 6.8% of Altium Capital Management LLC's portfolio, making the stock its 2nd largest holding. Altium Capital Management LLC owned 0.59% of ADMA Biologics worth $23,924,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. National Bank of Canada FI acquired a new position in shares of ADMA Biologics in the third quarter worth $35,000. GAMMA Investing LLC boosted its stake in shares of ADMA Biologics by 106.6% during the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock worth $32,000 after purchasing an additional 967 shares during the last quarter. Mark Sheptoff Financial Planning LLC purchased a new stake in shares of ADMA Biologics during the fourth quarter worth about $35,000. Vision Financial Markets LLC purchased a new position in shares of ADMA Biologics during the fourth quarter valued at approximately $51,000. Finally, AlphaQuest LLC acquired a new stake in ADMA Biologics during the fourth quarter worth approximately $84,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Stock Down 7.8 %

Shares of ADMA stock traded down $1.67 during mid-day trading on Monday, reaching $19.64. 5,775,212 shares of the company were exchanged, compared to its average volume of 3,625,634. The company has a market capitalization of $4.64 billion, a P/E ratio of 70.14 and a beta of 0.53. The business's 50 day simple moving average is $18.26 and its 200 day simple moving average is $18.21. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. ADMA Biologics, Inc. has a fifty-two week low of $6.19 and a fifty-two week high of $23.64.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 target price on shares of ADMA Biologics in a research report on Tuesday, March 4th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.